Sickle Cell, Thalassemia and Gene Therapy in Saudi Arabia: What Pharma Needs to Research Before Launch — Hematology market research Saudi Arabia for a 2026 launch

Hematology market research Saudi Arabia is a launch and access problem before it is a sizing problem. Premarital screening has been mandatory since 2004, Casgevy (exagamglogene autotemcel) has held an SFDA marketing authorisation since 9 January 2024, and hydroxyurea and matched-sibling transplant already sit in the pathway (Ministry of Health; Vertex, 9 January 2024). What a brand, HEOR or market-access team still cannot buy off the shelf is who is eligible, who is already treated, which wallet will pay, and which centre can infuse a one-time CRISPR product. This briefing uses only published sources. It sits alongside our healthcare market research hub and our ranking of top hematology market research companies in 2026.

What is hematology market research Saudi Arabia?

It is commissioned primary research on how sickle cell disease, β-thalassemia and — where relevant — malignant hematology are diagnosed, treated, funded and referred in the Kingdom. For a 2026 gene-therapy or disease-modifying launch, the unit of observation is the patient chart and the payer committee, not a vial and not a hematology-analyzer forecast.

Report publishers such as Grand View Research, 6Wresearch and Ken Research sell Saudi hematology diagnostics outlooks. Those pages often occupy the query “hematology market research Saudi Arabia”. Grand View Research’s public outlook puts the diagnostics category at USD 18.3 million in 2024. That is a reagent and instrument total. It does not say how many patients have recurrent VOCs, who is on hydroxyurea, which hospital can run apheresis and myeloablation, or whether Casgevy is on a formulary. Those answers require a custom brief. The global vendor comparison for that brief is our page on top hematology market research companies in 2026.

A usable hematology study in Saudi Arabia usually needs:

• Anonymous patient-record forms completed by treating hematologists, with incident and prevalent cases quota-controlled separately.
• Results split by region (Eastern, Jazan, Makkah, Riyadh and other), by public versus military or National Guard versus private, and by nationality.
• Payer and Pharmacy and Therapeutics interviews that treat MOH, NUPCO, CHI and each hospital formulary as different decisions (PPRI 2024; CHI).
• Arabic and English instruments, and sites in Dammam/Qatif, Jazan, Jeddah and Riyadh — not a Gulf average.

Country context sits on healthcare market research in Saudi Arabia, SFDA market access strategy and HEOR consulting in Saudi Arabia.

How common is the sickle cell thalassemia market Saudi Arabia?

Ask every provider which baseline it uses. Premarital screening measures adults who reach marriage age. It under-counts children who die early and the more severe Western phenotype (Jastaniah, 2011). Newborn and clinic counts are different methods. They are not a time series.

The first two programme years (2004–2005) screened 488,315 people: sickle-cell trait 4.20%, sickle-cell disease 0.26%, thalassemia trait 3.22%, thalassemia disease 0.07%. Among 2,375 high-risk couples the programme reached by telephone, 89.6% still married (Alhamdan et al., 2007). The Healthy Marriage programme now runs through more than 160 accredited governmental centres and more than 70 private centres nationwide (Al-Shroby et al., 2024).

The six-year national file (2004–2009) examined 1,572,140 people. Sickle-cell positivity was 45.1 per 1,000 (42.4 carriers, 2.7 cases). β-thalassemia positivity was 18.5 per 1,000 (18.0 carriers, 0.5 cases). The Eastern region was 134.1 per 1,000 for sickle cell and 59.0 per 1,000 for β-thalassemia. At-risk couples fell from 10.1 to 4.0 per 1,000, and voluntary cancellation of those proposals rose from 9.2% to 51.9%. The East held 58% of detected at-risk marriages (Memish and Saeedi, 2011; Memish et al., 2011).

The largest later file is Aljabry and colleagues’ 2011–2018 extract from the SEHA platform: 1,871,184 people, mean age 30.2. Abnormal results 6.0%. HbS 88,431 people (4.7%), of which HbSA 83,013 (4.4%) and HbSS 4,728 (0.3%). β-thalassemia 22,420 people (1.2%): 21,512 trait, 908 disease genotypes. Among sickle-cell disease presentations, 87.3% were HbSS, 12.5% HbS-β thalassemia, and 0.2% HbSC or HbSD. The Eastern and Jazan regions were five and six times Riyadh. There was no significant 2011–2018 trend in sickle-cell trait (387–471 per 10,000) or sickle-cell disease (24–31 per 10,000) (Aljabry et al., 2024).

Alsaeed and colleagues’ 2011–2015 cut puts sickle-cell trait at 135.7 per 1,000 in Jazan and 114.4 per 1,000 in the Eastern region, and sickle-cell disease at 9.8 per 1,000 in the East (Alsaeed et al., 2018). Jastaniah, reviewing Eastern newborn screening, reported about 21% trait and 2.6% disease in that regional newborn series — higher than the Eastern premarital figures of about 17% and 1.2% — because premarital screening misses children who do not survive to marriage (Jastaniah, 2011).

A community survey of 45,682 Saudi children and adolescents found 108 with SCD, or 24 per 10,000 (Al-Qurashi et al., 2008). Applying a 1–3 per 1,000 modelled prevalence to about 18.8 million Saudi nationals in the 2022 census, Al-Judaibi and colleagues estimated 18,800–56,000 people living with SCD (Al-Judaibi et al., 2025). Vertex’s approval note said only “thousands” (Vertex). Those three headcounts are three methods. A launch model that picks one and hides the range will be sent back.

The addressable adult population is also split by nationality. GASTAT’s mid-2024 estimate is 35.3 million residents, 19.6 million of them Saudi and about 15.7 million non-Saudi (GASTAT). Premarital files describe people seeking a marriage certificate. Entitlement, hospital channel and out-of-pocket exposure still have to be researched by nationality. Do not apply an Eastern premarital rate to 35.3 million residents and call it demand.

Two clinical phenotypes sit inside the same national label. Eastern disease is often the milder Arab-Indian haplotype, with higher fetal hemoglobin and more persistent splenomegaly; Western disease is more often the severe Benin haplotype (Jastaniah, 2011). A gene-therapy forecast that treats “Saudi SCD” as one severity will mis-state both VOC burden and eligibility.

What does hydroxyurea use tell a launch team?

Hydroxyurea is the disease-modifying layer a gene-therapy or new-agent brief has to sit beside. The published Saudi numbers do not agree, because they do not measure the same thing.

Alsaffar and colleagues reviewed 2,816 SCD clinic records from Al-Qatif Central Hospital and King Fahad Hospital in Hofuf (June 2021–May 2023) and found a 56% prevalence of hydroxyurea prescription. Younger patients were more often prescribed it; young males more than young females, with the pattern reversing after age 36. Hydroxyurea users were also more likely to have paracetamol, NSAIDs and opioids co-prescribed. The authors read that pattern as a compliance and adherence problem, not as proof of 56% persistent use (Alsaffar et al., 2024).

A 2022 Eastern-region survey of 202 patients and caregivers found 38.1% currently using hydroxyurea, 15.8% who had stopped, and 46% who had never used it. Among never-users, 40.9% said it was never offered and 34.4% had never heard of it (Cureus 2022). In Jazan, Gohal and colleagues found that more than 80% of participating parents said one or more of their children were receiving hydroxyurea — a parent-reported pediatric figure, not a national adult share (Gohal et al., 2022).

Where hydroxyurea is used, the published effect sizes are local. A single-centre cohort of 156 patients (mean age 12.69; mean dose 16.52 mg/kg/day) reported a mean reduction of 1.36 vaso-occlusive events per patient per year after at least 12 months (Al-Anazi et al., 2022). At King Saud Medical City in Riyadh, 82 eligible children had an 80% reduction in VOC and a 73% shorter length of stay after hydroxyurea (Bin-Saad et al., 2020). Those are effectiveness papers. They are not a 2026 treated-share tracker.

Two later disease-modifying agents cannot be assumed as a 2026 step. The European Medicines Agency recommended revoking crizanlizumab (Adakveo) in May 2023 (EMA, 26 May 2023). The U.S. FDA announced Pfizer’s voluntary withdrawal of voxelotor (Oxbryta) in September 2024 (FDA, September 2024). A Saudi brief should ask what centres did after those global actions. It should not invent an SFDA status that is not on a current SFDA page.

What does HSCT already do that gene therapy must sit beside?

Allogeneic transplant from a matched related donor is the curative option Saudi tertiary centres already publish. It is the comparator a Casgevy brief will be asked about.

Al-Jefri and colleagues reported 129 consecutive children (age at transplant ≤14) who received matched-related-donor HSCT for severe SCD at KFSH&RC Riyadh between January 2006 and December 2020. Indications were cerebral vasculopathy in 74 (57%), recurrent VOC in 47 (36%), recurrent acute chest syndrome in 5 (4%) and osteonecrosis in 3 (2%). Median age was 9.1 years. Ten-year overall survival was 94% and event-free survival 91%; with busulfan/cyclophosphamide/ATLG, OS was 97.4%. Acute GVHD occurred in 20% and chronic GVHD in 9%. Among patients older than 13 at last follow-up, 46% had a long-term complication, including gonadal failure (Al-Jefri et al., 2025). Variable hydroxyurea compliance before transplant was 60%; 52% of the cerebral-vasculopathy group were on regular monthly transfusion with iron chelation (Al-Jefri et al., 2025).

A 2020 Eastern Mediterranean review said KFSH&RC had performed approximately 200 matched-sibling SCD transplants by December 2018 — the authors labelled that figure a centre questionnaire, not a registry extract (Alsultan et al., 2020). Across four leading Saudi HSCT centres, 6,184 transplants had been performed by late 2016, 5,340 of them at KFSH&RC Riyadh, which opened the first unit in the WHO Eastern Mediterranean Region in 1984 (Aljurf et al., 2020).

Those papers describe matched-related-donor, mostly pediatric, myeloablative transplant. They do not describe how many 12- to 35-year-olds without a matched sibling are referred, wait-listed or declined. That gap is the gene-therapy research question. See also how hematology PRFs differ from transplant-centre case series.

Casgevy is approved. What is not yet published?

On 9 January 2024 Vertex announced that SFDA had granted marketing authorisation for CASGEVY (exagamglogene autotemcel) for people 12 years of age and older with SCD or transfusion-dependent β-thalassemia. It was the first medicine evaluated through SFDA Breakthrough Designation and Vertex’s first Saudi approval. Vertex wrote that Saudi Arabia has “among the highest prevalence rates of SCD and TDT in the world, with thousands of patients.” One authorized treatment centre was already activated. Vertex said it was working to qualify additional hospitals, including King Faisal Specialist Hospital, and “to secure listing on hospital formularies to support reimbursement as soon as possible” (Vertex, 9 January 2024; Nasdaq / Vertex). The Nasdaq version of the same release names the Ministry of National Guard Health Affairs as that first ATC (Nasdaq / Vertex).

The SFDA approval page still lists those two indications — SCD with recurrent VOCs, and TDT, both from age 12 — and was last updated on 30 September 2026 (SFDA). The May 2024 handling guide, approved by SFDA, repeats the same label and the mobilisation rules (no G-CSF in SCD; stop hydroxyurea, crizanlizumab and voxelotor before mobilisation) (SFDA handling guide).

What the public record does not yet give a launch team:

• A brand-level public formulary or NUPCO award for Casgevy. Vertex’s own January 2024 language was that listing still had to be secured (Vertex). CHI’s formulary is an SFDA-registered essential list; additions go through a hospital P&T committee (CHI). Government inclusion still runs through hospital P&T and, for national supply, NUPCO (PPRI 2024).
• A published treated-patient count. SFDA lists an ongoing Phase 4 registry of patients treated with exa-cel in the Kingdom (protocol 290-103, Vertex-sponsored, status Ongoing as of 8 May 2025) (SFDA registry). The page does not publish n.
• A published eligible-patient funnel by region, genotype, VOC count, transfusion dependence, age band or centre.
• A published outcomes-based or managed-entry contract. A January–February 2025 Delphi of 19 Saudi policymakers, clinicians, health economists and formulary leads reached consensus on 88 statements about drugs for rare diseases. Economic and budgetary constraints ranked highest; experts also flagged inconsistent reimbursement decisions and difficulty with managed-entry agreements (Abu Esba et al., 2025).

Payers already fund SCD. Shdaifat and colleagues interviewed 217 Saudi adults in Dammam Medical Complex and Al-Qatif Central Hospital and estimated SAR 181,899 (US$48,506) per patient per year from a societal perspective: SAR 80,306 (US$21,415) healthcare and SAR 101,594 (US$27,092) productivity (Shdaifat et al., 2024). A single-centre pediatric chart review of 100 patients (mean age 10.21; 96% HbSS) put mean annual direct medical cost at US$26,626, or US$14,605 after adjustment; 61% had had at least one red-cell exchange, 45% at least one VOC, and 59% at least one hospitalisation in 12 months (Healthcare 2025). A budget-impact that only prices the gene-therapy invoice, and ignores VOC admissions and exchange transfusion, answers the wrong question. That design sits on budget-impact modelling in Saudi Arabia.

What should hematology market research Saudi Arabia measure before launch?

Design the study backwards from the decision — a hospital formulary, a NUPCO cycle, a CHI addition, or a first-ATC capacity plan.

• Epidemiology baseline. State whether the model uses Aljabry 2011–2018 (adults at marriage), Alsaeed regional rates, Al-Qurashi’s pediatric 24 per 10,000, Jastaniah’s Eastern newborn pair, or the 18,800–56,000 modelled range — and test the others.
• Eligibility for the labelled indication. Age 12+, recurrent VOCs or TDT, genotype (HbSS vs HbS-β), and fitness for mobilisation and busulfan conditioning (SFDA; handling guide).
• Hydroxyurea layer. Prescription versus current use versus persistence, by region and by public versus other channels.
• HSCT layer. Who has a matched sibling, who is referred, who is declined, and what families are told about fertility (Al-Jefri et al., 2025).
• Payer and ATC layer. MOH, National Guard, military, KFSH&RC, CHI-insured private and self-pay, interviewed separately (PPRI 2024).
• Share of treated patients. Anonymous PRFs so new starts and continuing patients are two numbers, as set out on the hematology ranking.

For neighbouring systems do not import a Gulf average. Compare healthcare market research in the UAE, Egypt and Kuwait. A Saudi CHI or NUPCO answer is not a DHAMAN or UAE Thiqa answer.

How should you commission the study?

• How many hematologists, pediatric hematologists and transplant physicians will you recruit, and from which regions — Eastern, Jazan, Makkah and Riyadh at minimum?
• Will results be reported by nationality, by public versus military/National Guard versus private, and by new versus current cases?
• Which prevalence baseline will you use, and why?
• Will the discussion guide treat hydroxyurea, HSCT and Casgevy as three layers, not one “hematology” share?
• Are questionnaires available in Arabic and English?
• Who owns the data, and can it be re-cut after a formulary question changes?

Desk-research diagnostics reports remain useful for a first cut of laboratory capacity. Grand View Research, 6Wresearch and Ken Research publish Saudi hematology-diagnostics pages that often appear for this query. Use them to triangulate analyzer and reagent spend. Do not take them to a P&T meeting as the evidence pack for a gene therapy.

A physician-survey design is covered on physician surveys in Saudi Arabia. For the access dossier, see SFDA market access strategy and top healthcare market research companies in Saudi Arabia.

Why choose BioNixus for hematology market research in Saudi Arabia?

BioNixus is a primary market research and market access consultancy for pharmaceutical, medical device and healthcare companies, founded in 2012. It has served 118 clients in 48 countries, has run 127 studies so far in 2026 and works with a network of about 3,200 physicians. Custom study pricing is typically $10k–$60k. Regional leadership offices are in Sheridan, Wyoming (US headquarters), London EC1V 2NX and Cairo (Sheikh Zayed, Giza). Dubai, Al Khobar and Salmiya, Kuwait (Olympia Mall) are field offices, and it is in the process of opening a São Paulo office by the end of 2026. LATAM work is covered from the US office with a strong local consultant network.

Choose BioNixus when the decision depends on why Saudi hematologists, transplant teams and payers act as they do, rather than on a diagnostics-market total. Each study is built around one decision — a formulary, a tender, an ATC capacity plan — and is reported as share of treated patients. The delivery commitment is Guaranteed in writing. That guarantee covers the agreed scope and timeline, not the accuracy of findings. Where reviews are relevant, BioNixus has 40 client reviews.

See also healthcare market research in Saudi Arabia, pharmaceutical companies in Saudi Arabia, top healthcare market research firms in Saudi Arabia and the 2026 hematology ranking.

To brief a Saudi sickle-cell, thalassemia or gene-therapy study, use the BioNixus contact form or email admin@bionixus.com.

References

1. Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia. Ann Saudi Med. 2011;31(3):229–235. doi:10.4103/0256-4947.81527. 1,572,140 people screened, 2004–2009. Source (accessed 13 October 2026).
2. Memish ZA, Owaidah TM, Saeedi MY. Marked regional variations in the prevalence of sickle cell disease and β-thalassemia in Saudi Arabia: findings from the premarital screening and genetic counseling program. J Epidemiol Glob Health. 2011;1(1):61–68. Source (accessed 13 October 2026).
3. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9(6):372–377. doi:10.1097/GIM.0b013e318065a9e8. 488,315 people screened. Source (accessed 13 October 2026).
4. Aljabry M, Sulimani S, Alotaibi G, Aljabri H, Alomary S, Aljabri O, Sallam M, Alsultan A. Prevalence and regional distribution of beta-hemoglobin variants in Saudi Arabia: insights from the national premarital screening program. J Epidemiol Glob Health. 2024;14(3):1242–1248. doi:10.1007/s44197-024-00281-x. 1,871,184 people, 2011–2018. Source (accessed 13 October 2026).
5. Alsaeed ES, Farhat GN, Assiri AM, et al. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. J Epidemiol Glob Health. 2018;7(Suppl 1):S41–S47. Source (accessed 13 October 2026).
6. Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011;31(3):289–293. doi:10.4103/0256-4947.81540. Reviews premarital versus Eastern newborn screening and the mild Eastern versus severe Western phenotypes. Source (accessed 13 October 2026).
7. Al-Qurashi MM, El-Mouzan MI, Al-Herbish AS, Al-Salloum AA, Al-Omar AA. The prevalence of sickle cell disease in Saudi children and adolescents. A community-based survey. Saudi Med J. 2008;29(10):1480–1483. Source (accessed 13 October 2026).
8. General Authority for Statistics (GASTAT). Population Estimates Statistics 2024 (English). Mid-2024: 35.3 million residents; 19.6 million Saudis; about 15.7 million non-Saudis. Source (accessed 13 October 2026).
9. Al-Judaibi B, Alzahrani H, Alahmari A, et al. Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia. Saudi J Gastroenterol. 2025;31(2). Applies a 1–3 per 1,000 prevalence range to about 18.8 million Saudi nationals in the 2022 census to estimate 18,800–56,000 patients. Source (accessed 13 October 2026).
10. Ministry of Health, Saudi Arabia. The Healthy Marriage Program (policy 005). Premarital screening and counselling mandated by Council of Ministers Resolution no. 4/B/54504 dated 15/11/1424 H. Source (accessed 13 October 2026).
11. Al-Shroby WA, et al. Outcomes of the premarital screening program in Riyadh Region, KSA in 2021–2022: a cross-sectional study. J Family Med Prim Care. 2024. Notes more than 160 accredited governmental centres and more than 70 private centres nationwide. Source (accessed 13 October 2026).
12. Alsaffar N, Alsaleh MA, Alsaleh AA, et al. Prescribing hydroxyurea in sickle cell disease patients: the pattern and association with co-prescribed medications used to manage the disease complications. J Clin Med. 2024;13(20):6254. doi:10.3390/jcm13206254. 2,816 patients at Al-Qatif Central Hospital and King Fahad Hospital, Hofuf, June 2021–May 2023; 56% hydroxyurea prescription. Source (accessed 13 October 2026).
13. Impact of hydroxyurea therapy in reducing pain crises, hospital admissions, and length of stay among sickle cell patients in the Eastern Region of Saudi Arabia. Cureus. 2022;14(11):e31527. doi:10.7759/cureus.31527. 202 respondents; 38.1% currently using hydroxyurea. Source (accessed 13 October 2026).
14. Gohal GA, Gosadi IM, Cittana Iqbal BA, et al. Utilization of hydroxyurea among patients diagnosed with sickle cell disease in Jazan, Saudi Arabia. Patient Prefer Adherence. 2022;16:3229–3239. More than 80% of participating parents said one or more of their children were receiving hydroxyurea. Source (accessed 13 October 2026).
15. Al-Anazi A, et al. The impact of hydroxyurea on the rates of vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study. 156 patients; mean hydroxyurea dose 16.52 mg/kg/day; mean VOC reduction 1.36 events per patient per year. Source (accessed 13 October 2026).
16. Bin-Saad K, et al. The role of hydroxyurea in decreasing the occurrence of vaso-occlusive crisis in pediatric patients with sickle cell disease at King Saud Medical City in Riyadh, Saudi Arabia. Saudi Med J. 2020;41(1):46–52. 82 eligible children; 80% reduction in VOC and 73% shorter length of stay after hydroxyurea. Source (accessed 13 October 2026).
17. Al-Jefri A, Al-Hashem F, Siddiqui K, et al. Hematopoietic stem cell transplantation in severe pediatric sickle cell disease: outcome and long-term complications, Saudi experience at King Faisal Specialist Hospital, Riyadh, Saudi Arabia. Mediterr J Hematol Infect Dis. 2025. 129 matched-related-donor transplants, 2006–2020; 10-year OS 94%, EFS 91%. Source (accessed 13 October 2026).
18. Alsultan A, et al. Hematopoietic stem cell transplantation for patients with sickle cell disease in the Eastern Mediterranean. Hematol Oncol Stem Cell Ther. 2020;13(2). Reports that KFSH&RC had performed approximately 200 matched-sibling SCD transplants by December 2018 (centre questionnaire). Source (accessed 13 October 2026).
19. Aljurf M, et al. Hematopoietic stem cell transplantation in Saudi Arabia between 1984 and 2016: experience from four leading tertiary care hematopoietic stem cell transplantation centers. Hematol Oncol Stem Cell Ther. 2021. KFSH&RC Riyadh 5,340 HSCTs to 2016; four centres 6,184. Source (accessed 13 October 2026).
20. Vertex Pharmaceuticals. Vertex announces approval of first CRISPR/Cas9 gene-edited therapy, CASGEVY, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Kingdom of Saudi Arabia. 9 January 2024. SFDA marketing authorisation for people 12 years and older; first SFDA Breakthrough Designation; one authorized treatment centre already activated; working to qualify KFSH and to secure hospital-formulary listing. Source (accessed 13 October 2026).
21. Vertex / Nasdaq press release, 9 January 2024. Names the Ministry of National Guard Health Affairs (MNGHA) as the first Authorized Treatment Center in Saudi Arabia and King Faisal Specialist Hospital as a centre Vertex was working to qualify. Source (accessed 13 October 2026).
22. Saudi Food and Drug Authority. Drug approvals page for Casgevy. Indications: SCD in patients 12 years and older with recurrent vaso-occlusive crises; transfusion-dependent β-thalassemia in patients 12 years and older. Page last updated 30 September 2026. Source (accessed 13 October 2026).
23. Saudi Food and Drug Authority. Registry-based study of patients treated with exagamglogene autotemcel (exa-cel) in the Kingdom of Saudi Arabia. Protocol 290-103; sponsor Vertex; Phase 4; status Ongoing as of 8 May 2025. Source (accessed 13 October 2026).
24. Vertex / SFDA. CASGEVY handling and administration guide, Kingdom of Saudi Arabia, version 1.0. Date of preparation May 2024; approved by SFDA May 2024. Restates the 12+ SCD (recurrent VOC) and TDT indications. Source (accessed 13 October 2026).
25. Abu Esba LC, Yousef CC, Khan MA, et al. Challenges in evaluation and reimbursement of drugs for rare diseases in Saudi Arabia: a Delphi expert consensus. J Pharm Policy Pract. 2025. Nineteen experts, January–February 2025; consensus on 88 statements across eight themes; economic and budgetary constraints the highest concern. Source (accessed 13 October 2026).
26. Shdaifat E, Abu-Sneineh F, Alsaleh N, Ibrahim A. Economic burden of sickle cell disease in Saudi Arabia. Value Health Reg Issues. 2024;44:101038. doi:10.1016/j.vhri.2024.101038. 217 adults in the Eastern region; mean societal cost SAR 181,899 (US$48,506). Source (accessed 13 October 2026).
27. The direct medical costs of sickle cell disease in Saudi Arabia: insights from a single center study. Healthcare (Basel). 2025;13(4):420. 100 patients, mean age 10.21 years, 96% HbSS; mean annual direct medical cost US$26,626; adjusted mean US$14,605. Source (accessed 13 October 2026).
28. PPRI / Austrian National Public Health Institute. Healthcare system and pharmaceutical pricing in Saudi Arabia (2024). Describes SFDA pricing, NUPCO group purchasing, hospital Pharmacy and Therapeutics committees, and Council of Health Insurance control of private reimbursement. Source (accessed 13 October 2026).
29. Council of Health Insurance. CHI Drug Formulary (Dhaman). Open formulary of SFDA-registered medicines; addition requests go through a hospital Pharmacy and Therapeutics Committee or the assigned medical director. Source (accessed 13 October 2026).
30. U.S. Food and Drug Administration. FDA alerting patients and health care professionals about the voluntary withdrawal of Oxbryta (voxelotor) from the market. September 2024. Source (accessed 13 October 2026).
31. European Medicines Agency. EMA recommends revoking authorisation of sickle cell disease medicine Adakveo (crizanlizumab). 26 May 2023. Source (accessed 13 October 2026).
32. Grand View Research. Saudi Arabia hematology diagnostics market outlook. Public 2024 revenue USD 18.3 million (instrument and consumable sizing, not primary SCD or gene-therapy research). (accessed 13 October 2026).
33. 6Wresearch. Saudi Arabia hematology diagnostics and hematology analyzer and reagents report pages. (accessed 13 October 2026).
34. Ken Research. Saudi Arabia hematology diagnostics market report pages. (accessed 13 October 2026).